SS&C Technologies Holdings Inc. Common Stock vs Vir Biotechnology Inc. Common Stock — how do they compare? SS&C Technologies Holdings Inc. Common Stock trades at $82.08 (market cap $19.13B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: SS&C Technologies Holdings Inc. Common Stock is far larger — about 10.6× Vir Biotechnology Inc. Common Stock's market cap, and SS&C Technologies Holdings Inc. Common Stock pays a 1.47% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold SS&C Technologies Holdings Inc. Common Stock for 0 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| SSNC | VIR | |
|---|---|---|
Market Cap | $19.13B | $1.80B |
Volume | 1,333,448 | 1,782,836 |
Sector | Technology | Health |
52-Week High | $89.62 | $11.78 |
52-Week Low | $62.05 | $5.12 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $26.47B | $1.36B |
Dividend Yield | 1.47% | — |
Signals from Pluang's Aura AI — not financial advice
SSNC trades at $81.52, up 0.65% on the day, with a neutral technical signal. The company has consistently beaten earnings estimates in recent quarters (Q4 2025, Q1 2026, Q2 2026) and shows solid fundamentals, including a 13.16% net income margin and 12.73% ROE. Recent news highlights new client wins and AI-driven product enhancements, reinforcing its market position.
The outlook is positive, supported by strong analyst consensus (70.83% Buy rating) and a $91.50 price target, implying ~12% upside. Key risks include execution of growth initiatives and competitive pressures in the financial technology sector. The stock presents a compelling opportunity for investors seeking a fundamentally sound company with recurring revenue streams.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
SS&C Technologies Holdings, Inc. provides software and outsourced services for financial services and healthcare organizations, covering fund accounting, portfolio management, trading support, and regulatory reporting, and operates as a hedge fund and private equity administrator and mutual fund transfer agent.
Read more on SSNC →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →